To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Ryan Reynolds in emotional plea as dad loses fight with Parkinson’s disease
Actor honours father and urges donations for Parkinson’s research
2 weeks ago
EPDA signs new charter on workplace rights
The European Parkinson’s Disease Association (EPDA) has signed the Dying to Work Charter – a pledge protecting the workplace rights of people with serious conditions. The charter – part of the Trade Union Congress’ wider Dying to Work campaign – has so far protected over half a million workers in the UK. The Dying to Work campaign group, chaired by MEP Rory Palmer, is calling on the European Union to amend its current legislation. The campaign is asking for serious conditions to be identified as a ‘protected characteristic’ – meaning employees would enjoy a protected period after diagnosis which would ensure the couldn’t be unfairly dismissed. Russell Patten, secretary general at the EPDA, said: “At the EPDA, we are committed to improving employment conditions, reducing stigma and ensuring accessibility to essential services for all people with Parkinson’s disease.” Image: Rory Palmer MEP (left) and Russell Patten, secretary general at the EPDA…
Scientists at the National University of Ireland Galway have created a wearable device that they believe will help people with Parkinson’s to walk more easily. The device, named cueStim, is worn around the waist and delivers fixed rhythmic sensory stimulation to the wearer. This will counteract ‘freezing of gait’ symptoms that are often experienced by people living with the condition. The scientists collaborated with professionals from UK medical board NHS Greater Glasgow and Clyde to test the device, and found that it significantly reduced the time taken for a person with Parkinson’s to complete walking tasks. Gearóid Ó Laighin, professor of electrical engineering at NUI Galway, said: “We are now seeking additional clinical partners to work with NUI Galway in carrying out a comprehensive long-term clinical evaluation of cueStim in enhancing the quality of life of people with Parkinson’s disease through a funded programme of research.”
Could robots replace animals in Parkinson’s medical trials?
Researchers at Heriot-Watt University, Edinburgh, UK, are testing new treatments for Parkinson’s disease on robots. Academics at the university – who are collaborating with the International Institute for Neurosciences of Natal, Brazil – will use computer models of the human brain to simulate the effect medication has on people living with Parkinson’s. The study – which is the first of its kind – could lead to a major shift in the way that Parkinson’s treatments are tested in the future, and potentially put an end to animal testing. Dr Patricia A Vargas, the lead collaborator of the study said: “Our hope is two-fold – to reduce and replace animals in research, and to help and inform new therapies, treatments and even the cure for this debilitating disease.”